Supplemental Figure 1
Trace from a sucrose density gradient separation of lysates made from the MCF7 cell line.

Supplemental Figure 2
BCL2 family protein expression in response to 4EGI-1
A) Westerns showing BCL2A1, BCL2L1 and MCL1 expression following treatment with LY294002, PI-103 and 4EGI-1 in 4 patients. GAPDH is a loading control. Patient identifiers (see Table 1) are given beside the western panels.
B) CLL cells were labeled with $[^{35}\text{S}]$methionine and chased for the times indicated in the presence or absence of 4EGI-1. At the end of the indicated intervals, cells were lysed and MCL1 protein was immunoprecipitated using anti-MCL1 antibodies. The immunoprecipitated material were separated by SDS-PAGE or subjected to western blotting analysis using anti-MCL1 antibodies.
C) Westerns showing BIM expression in 3 patients on stromal cell/CD154 culture in the presence and absence of 4EGI-1. GAPDH is a loading control.

Supplemental Figure 3
Relative expression of pro-survival proteins and synergy between 4EGI-1 and ABT-737 across a range of expression levels. (A) Distribution of BCL2A1, BCL2L1 and MCL1 expression in 36 patients. Densitometry data derived from westerns was corrected for differences in protein loading, both within and between gels. Median 10th, 25th, 75th and 90th centiles are shown as box and whisker plots. MCL1 expression is significantly different from BCL2A1 expression ($P<0.01$; two tailed paired t-test). (B) Unsupervised hierarchical clustering (using average dot product as a distance metric and single linkage clustering, Multi-Experiment Viewer MeVv4.4 (52)) to show relative differences in BCL2A1, BCL2L1 and MCL1 expression in a population of CLL patients. In 13 of the 36 patients the enhancement of ABT-737 mediated apoptosis by 4EGI-1 was measured and scored (30). ++++ strong synergy, +++ synergy, ++ moderate synergy, + slight synergy, o nearly additive and – slight antagonism.
Willimott et al.
Supplemental Figure 1
Willimott et al.
Supplemental Figure 3